In this CE activity, experts in the field address unmet needs in IBD care, examine the role of the TL1A pathway in IBD, report the latest clinical evidence on emerging TL1A inhibitors, and discuss how TL1A may shift treatment paradigms for UC and CD.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 6900 Grove Road
Pricing
100% of listed courses are free
256 of 256 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Rhinology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1.25 credits
- Commercial Support
-
ReleasedDec 1, 2025
-
Last day to claim creditDec 1, 2026 7 weeks left
-
Vindico Medical Education, LLC IBD Advancements: The Promise of TL1A-Targeted Therapies
-
Vindico Medical Education, LLC TL1A Inhibition for IBD: Emerging Therapies at the Intersection of Inflammation and Fibrosis
-
Vindico Medical Education, LLC Targeting TL1A in IBD to Treat Both Inflammation and Fibrosis A Wheel of Knowledge Challenge!
